Strategic Financial Concepts LLC Makes New Investment in GSK plc (NYSE:GSK)

Strategic Financial Concepts LLC acquired a new stake in GSK plc (NYSE:GSK) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 119,236 shares of the pharmaceutical company’s stock, valued at approximately $4,033,000.

Other hedge funds also recently modified their holdings of the company. FMR LLC boosted its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after buying an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after acquiring an additional 833,080 shares during the period. Bridgewater Associates LP boosted its position in shares of GSK by 107.3% in the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after acquiring an additional 500,010 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of GSK by 420.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 564,934 shares of the pharmaceutical company’s stock valued at $23,095,000 after acquiring an additional 456,319 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the subject of a number of recent research reports. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Six analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Down 1.0 %

Shares of GSK opened at $36.03 on Monday. The firm has a 50 day simple moving average of $34.25 and a two-hundred day simple moving average of $37.56. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.53. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a market cap of $74.68 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.42 and a beta of 0.64.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts forecast that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.36%. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio (DPR) is presently 93.08%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.